Patents
& Pipeline
IGC Pharma holds a diverse portfolio of granted and pending patents focused on innovative small molecules and pharmaceutical compositions.
These intellectual properties aim to address unmet medical needs in Alzheimer’s Disease, central nervous system disorders, epilepsy, cancer, eating disorders, and more
Safe, well-tolerated and may reduce agitation and
caregiver distress in Alzheimer’s disease.
Pipeline
While IGC-AD1 is the furthest in the clinical trials pipeline, IGC Pharma is actively building a portfolio of both plant-derived and manufactured molecules that can address multiple areas of unmet medical needs.
Intellectual Property and Patents
While IGC-AD1 is the furthest in the clinical trials pipeline, IGC Pharma is actively building a portfolio of both plant-derived and manufactured molecules that can address multiple areas of unmet medical needs.
